Introduction
============

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic inflammatory airway diseases with different underlying mechanisms.[@b1-copd-13-591] However, they are characterized by a complex heterogeneity and the existence of different overlapping phenotypes that influence the response to treatment. As a result, it is sometimes difficult to determine whether a patient is suffering from asthma, COPD, or the overlap of both the conditions. This controversy led to a theory -- the so-called "Dutch hypothesis" -- that postulates that chronic obstructive airway disease (COAD) may occur on a continuum, with "pure" forms of asthma and COPD representing the extremes of the same disease and the various forms of COAD being different expressions of a single disease entity.[@b2-copd-13-591] To make things even more complicated, clinicians have long acknowledged the existence of a group of patients with COAD who display characteristics of both asthma and COPD. This condition has been recently regaining attention in the medical literature, and it has ended up being named ACO (asthma--COPD overlap).[@b3-copd-13-591],[@b4-copd-13-591] ACO is an umbrella term that encompasses patients with COPD and eosinophilic inflammation and smoking asthmatics with a predominantly neutrophilic inflammation and irreversible airway obstruction. Therefore, the whole picture of COAD is blurred, with different and overlapping phenotypes that are difficult to clinically distinguish from one to another with the lack of an accurate biomarker that is able to distinguish these entities. We have recently shown that the presence of a Th2 signature, defined by eosinophils in sputum \>3% or blood eosinophils \>300 cells/µL, could help to identify and treat the patients with COAD.[@b5-copd-13-591]

In a clinical scenario of great heterogeneity, breaking down complex data into its component parts and plotting them to show their interdependences and interrelationships would help us to clarify the motley nature of COAD. The aim of this study was to investigate the systemic "molecular fingerprinting" of the different clinical phenotypes of COAD. In doing so, the main objective was to evaluate the heterogeneity of inflammation in patients with COAD by using discriminant and network analysis. The comparison of correlation networks can provide new insights into the complexity and heterogeneity of ACO. As secondary end points, we assessed the capacity of these biomarkers to predict the clinical COAD phenotype, the Th2-high pattern, and the relation between these biomarkers and clinical significant outcomes: exacerbations and symptoms.

Materials and methods
=====================

Study design
------------

This cross-sectional, observational, multicenter study was carried out in 23 outpatient clinics from tertiary hospitals in Spain run by expert respiratory physicians. The design of the study has been described elsewhere.[@b5-copd-13-591] As described in detail previously,[@b5-copd-13-591] "male and female patients aged ≥40 years with chronic airflow obstruction (post-bronchodilator forced expiratory volume in the first second (FEV~1~)/forced vital capacity (FVC) \<0.70) and a history of physician-diagnosed asthma, COPD, or ACO (as defined below) who signed an informed consent form were included. Patients had to be in a stable condition and free from exacerbations for at least 3 months. Exclusion criteria included primary bronchiectasis, active cancer, other chronic inflammatory diseases, and poor performance status (defined as life expectancy of \<3 months)."

A blood sample was obtained to determine the number and percentage of blood eosinophils and quantification of immunoglobulin E, and serum was stored at −80°C for later determination of periostin and cytokines. The degree of compliance with inhalers was estimated by the test of adherence to inhalers.[@b6-copd-13-591]

The study was approved by the Research Ethics Committee of the Balearic Islands (code: IB2499/15). In addition, an independent ethics committee or institutional review board for each study center approved the final protocol.

Study protocol
--------------

All researchers were asked to recruit 12 consecutive patients with chronic obstructive airway disease: four nonsmoking asthmatics, four with COPD, two smoking asthmatics, and two with COPD with eosinophilia. The recruitment period was between October 2015 and March 2016. The flowchart of recruitment according to according to the STROBE statement (STrengthening the Reporting of OBservational studies in Epidemiology) has been published elsewere.[@b5-copd-13-591]

The study was conducted in a single visit in which the researchers obtained and recorded information in an electronic clinical research database: anthropometric data; smoking history; a previous history of atopy, rhinitis, nasal polyposis, and comorbidities; exacerbations in the previous year; symptoms assessed by the validated Spanish version of the COPD assessment test and by the asthma control test; pharmacologic treatments; and the degree of compliance with inhalers estimated by the test of adherence to inhalers.

Fractional exhaled nitric oxide was measured by using a chemiluminescence analyzer (NIOX; Aerocrine, Stockholm, Sweden) at a flow rate of 50 mL/s, in accordance with the recommendations of the American Thoracic Society/the European Respiratory Society task force.

Sputum induction
----------------

Before the induction of sputum, patients inhaled 400 µg of salbutamol. Briefly, the volume of the whole sputum was assessed, and an equal volume of dithioerythritol (Sigma, Munich, Germany) was added. The total cell count and viability were obtained simultaneously in a modified Neubauer counting chamber (Hausser Scientific, Horsham, PA, USA). Differential cell counts were expressed as the percentage of nonsquamous cells, and those with significant squamous contamination (\>80%) were excluded from the analysis.

Sample size calculation
-----------------------

An a priori sample size was calculated considering a statistical power of 80% and 5% of alpha error. A minimum of 100 asthma--COPD overlap (ACO) patients and 200 other chronic airway disease patients would be enough in order to identify statistically significant differences of ≥15% when compared with any of the reference groups, in most variables ranging from 10% up to 80% in ACO.

Definitions
-----------

### Asthma

Asthma with chronic airflow obstruction (post-bronchodilator FEV~1~/FVC \<0.70) was diagnosed according to the international guidelines,[@b7-copd-13-591] and they were either never-smokers or ex-smokers with a smoking history of ≤10 pack-years.

### COPD

COPD was diagnosed according to international recommendations[@b3-copd-13-591] by the presence of post-bronchodilator FEV~1~/FVC \<0.70 in patients with a smoking history of ≥10 pack-years in the absence of a clinical suspicion for asthma.

### ACO

As described in detail previously,[@b5-copd-13-591] we defined ACO as an umbrella term that encompasses two related -- with a similar underlying mixed (Th2 and non-Th2) inflammatory pattern and chronic airflow obstruction -- but distinct entities: smoking asthmatics (SA; asthma with chronic airflow obstruction and a smoking history ≥20 pack-years) and COPD with eosinophilia (COPD-e; COPD patients with eosinophil count ≥200 cells/µL in blood). We selected this threshold because below this cutoff patients are unlikely to have sputum eosinophilia, according to published evidence.[@b8-copd-13-591]

### COAD with Th2-high

Patients with chronic airflow limitation demonstrated post-bronchodilator FEV~1~/FVC \<0.70 and a sign of Th2 inflammation as described previously[@b5-copd-13-591] (eosinophil count ≥300 eosinophils/µL in blood or ≥3% in sputum).

### COAD with Th2-low

Patients with chronic airflow limitation demonstrated post-bronchodilator FEV~1~/FVC \<0.70 and no signs of Th-2 inflammation as described previously[@b5-copd-13-591] (eosinophil count ≤300 eosinophils/µL in blood and ≤3% in sputum).

### Th2/Th1 ratio

The ratios IL-13/IL-8 or IL-5/IL-8 were calculated to detect a predominant Th2 profile.

Measurements
------------

More detailed information about data management, pulmonary function tests, fractional exhaled nitric oxide (FeNO) measurement, and cell inflammatory counts in induced sputum can be found elsewhere.[@b5-copd-13-591] Periostin levels were measured by using a streptavidin-horseradish peroxidase enzyme-linked immunosorbent assay (ELISA) commercial kit (DuoSet^®^ ELISA; R&D Systems, Inc., Minneapolis, MN, USA), according to the manufacturer's instructions. The specificity of the periostin assay was 100%, and the detection limit was 180 ng/mL. In all the patients, serum periostin levels were measured in duplicate.

The concentrations of IL-5, IL-13, IL-8, IL-6, tumor necrosis factor-α (TNF-α), and IL-17 in serum were analyzed by using a human cytokine magnetic bead panel (Merck Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Assay sensitivity according to the manufacturer was as follows: 0.23 pg/mL for IL-13, 0.33 pg/mL for IL-17, 0.12 pg/mL for IL-5, 0.11 pg/mL for IL-6, 0.13 pg/mL for IL-8, and 0.16 pg/mL for TNF-α.

Network analysis
----------------

A network layout of the systemic inflammatory pattern (inflammome) in the three groups of participants was built following a previously validated method.[@b9-copd-13-591] Each node of the network represents one biomarker, its size being proportional to the percentage of the median in reference to maximal values for each variable. Nodes are linked if a statistically significant correlation (Spearman *p*\<0.05) was found.

Statistical analysis
--------------------

Data are expressed as mean (SD) for continuous normally distributed variables: univariate pair-wise comparisons were performed by using Student's *t*-tests, while one-way analysis of variance was used to compare more than two groups (Bonferroni correction was applied for pair-wise post hoc tests). Continuous variables with non-normal distributions were expressed as median (interquartile range \[P25--P75\]), and comparisons among groups were carried out by using the Mann--Whitney *U*-test or Kruskal--Wallis test with the Nemenyi post hoc test. For categorical variables, counts and percentages were given in each category, and groups were compared by means of *χ*^2^ tests, with Bonferroni correction for pair-wise comparisons. Correlations between continuous variables were estimated by using Spearman test.

To explore the association of biomarkers with the COAD categories (asthma, COPD, and ACO) and to assess the corresponding discrimination ability, a discriminant analysis (DA) was carried out fitting the linear combinations of biomarkers, which allowed the best classification of patients into the diagnostic groups. The results were visually summarized through a classification map, based on the DA estimates.

The reliability of biomarkers' concentration for the diagnosis of different COAD categories and Th2 profiles was assessed by estimating the corresponding receiver operating characteristic (ROC) curves with the corresponding 95% confidence intervals. Youden index was used for the determination of optimal cutoff values of the biomarkers. Sensitivity and specificity were also estimated for each cutoff.

All statistical analyses were performed by using the SPSS software (Version 19.0; IBM Corporation, Armonk, NY, USA).

Results
=======

Population characteristics
--------------------------

As described in detail previously,[@b5-copd-13-591] 292 patients with COAD were included in the study: 94 asthmatics, 89 COPD, and 109 ACO (44 SA and 65 COPD-e) patients. [Figure 1](#f1-copd-13-591){ref-type="fig"} shows the flowchart of patient recruitment. [Table 1](#t1-copd-13-591){ref-type="table"} reports the demographic, clinical, and functional characteristics of the entire sample. Briefly, patients showed a moderate degree of bronchial obstruction and mild-to-moderate level of symptoms as assessed by the COPD assessment test (CAT) and asthma control test (ACT) questionnaires. The average number of exacerbations during the last 12 months was 1.0. Baseline treatment was based on long-acting β~2~-agonist and inhaled corticosteroids (ICSs; 80%) and long-acting muscarinic antagonist (71%). All asthma patients, 66.3% of COPD patients, and 75% of ACO patients were treated with ICSs. No patient from the COPD or ACO group was being treated with oral corticosteroids, whereas 6.4% of the asthmatics were taking them. Interestingly, 17.5% of asthma patients and 8.6% of ACO patients were receiving omalizumab.

Cytokine and periostin values among the different diagnostic categories
-----------------------------------------------------------------------

[Table 2](#t2-copd-13-591){ref-type="table"} and [Figure 2](#f2-copd-13-591){ref-type="fig"} display the results of inflammatory markers measured in the three diagnostic categories. Th2-related cytokines (IL-13 and IL-5) showed highest median values in asthma and lowest median values in COPD, whereas they presented intermediate results in ACO. The only statistically significant difference was in IL-5 levels between asthma and COPD (2.09 vs 1.11 pg/mL; *p*=0.03). IL-17 and TNF-α levels were similar between the groups. Periostin levels were not different between the three categories. Non-Th2-related cytokines such as IL-8 were found to be increased in COPD and ACO compared with asthma (*p*\<0.001).

Th2/Th1 ratios (IL-5/IL-8 and IL-5/IL-13) were higher in asthma (0.25 and 0.43, respectively) than in the other categories without differences between ACO (0.14 and 0.14) and COPD (0.12 and 0.15).

Discriminant and network analysis
---------------------------------

Overall, the correlation between the cytokines was poor. It is worth emphasizing that correlation between IL-5 and IL-13 was 0.489 (*p*\<0.0001), and IL-17 correlated moderately with IL-5 (r=0.553; *p*\<0.0001), IL-13 (r=0.550; *p*\<0.0001), and IL-6 (r=0.579; *p*\<0.0001). IL-8 and TNF-α showed a weak correlation between them (r=0.207; *p*\<0.0001) and no statistically significant correlation with IL-5, IL-13, and IL-17. IL-6 correlated moderately with the other cytokines. Blood eosinophils correlated weakly with IL-5 (r=0.122; *p*=0.40) and with periostin (r=0.211; *p*\<0.0001). Periostin did not correlate significantly with blood cytokines.

Two principal components (linear combination of markers), explaining about 60% of the total variance in the data, were identified. The first discriminant score (DS1) was mainly characterized by the values of IL-5, IL-13, IL-6, and TNF-α, while IL-8 had more weight in the second discriminant score (DS2). [Figure 3](#f3-copd-13-591){ref-type="fig"} shows the scatterplot of individual values computed for each patient based on DS1 and DS2, identifying the patient's diagnostic category (asthma, COPD, and ACO). Patients from different categories had very similar DS values, so that a clear and distinct pattern could not be observed in cytokine relationship. Less than one half of the patients (42.8%) were correctly classified by the two estimated DSs, confirming the limited discrimination abilities of these markers.

The network representation of the weight and interaction of inflammatory markers (inflammome) in the three categories yielded two different scenarios, being IL-13 and IL-17 the most connected nodes but with different weights of the nodes, showing IL-5 and IL-8 with the most marked differences in node weight. The inflammome of ACO was a mixture of the two previous networks, being IL-5 and IL-8 equally important and with IL-13 and IL-17 still in the middle of the network ([Figure 4](#f4-copd-13-591){ref-type="fig"}).

Diagnostic accuracy of the potential biomarkers for the identification of different diagnostic categories or Th2-high and Th2-low inflammatory phenotypes
---------------------------------------------------------------------------------------------------------------------------------------------------------

Neither a single cytokine nor Th2/Th1 ratios yielded enough sensitivity and specificity to accurately identify the various diagnostic categories of COAD (asthma, COPD, and ACO). The area under the ROC curve (AUC) was \<0.7 in every case. [Table S1](#SD1-copd-13-591){ref-type="supplementary-material"} displays the AUCs for each cytokine or periostin and the diagnostic categories of COAD.

Some cytokines were more highly expressed in the Th2-high group compared with the Th2-low group ([Table 3](#t3-copd-13-591){ref-type="table"}), medians (interquartile ranges): IL-5 (1.96 \[0.87--3.34\] vs 1.51 \[0.29--2.88\] pg/mL; *p*=0.025), TNF-α (4.32 \[3.20--6.16\] vs 3.95 \[2.91--5.32\] pg/mL; *p*=0.055), and periostin (39.73 \[28.05--54.40\] vs 34.20 \[26.94--41.43\] ng/mL; *p*=0.005). No statistically significant differences were found between the two groups in the other analyzed cytokines, alone or in combination ([Table 3](#t3-copd-13-591){ref-type="table"}).

Again, since the AUC was \<0.7 in every case, neither a single cytokine nor periostin, nor any combination of them, yielded enough sensitivity and specificity to accurately predict the Th2-high and Th2-low molecular phenotype. A cutoff value of FeNO \>17 ppb showed better AUC (0.707 \[0.642--0.772\], *p*\<0.001) than the cytokines or periostin in blood ([Table 4](#t4-copd-13-591){ref-type="table"}).

Association of cytokines or periostin with clinical outcomes
------------------------------------------------------------

The values of the different cytokines or periostin (alone or in combination) were not different between the patients with (n=144) and without (n=148) exacerbations, between poorly controlled (ACT \<20 \[n=85\]) and well-controlled asthmatics (ACT ≥20 \[n=137\]), between symptomatic (CAT ≥10 \[n=163\]) and poorly symptomatic COPD patients (CAT \<10 \[n=81\]), and between those with FEV~1~ above the whole population median (1.505 mL) and those with FEV~1~ below the median.

Discussion
==========

In this study, we have found that the different inflammatory mechanisms involved in asthma and COPD may overlap in certain patients, leading to a mixture of Th2 and non-Th2 cytokine expression. ACO shows therefore a heterogeneous inflammatory process that overlaps the characteristics of both conditions: asthma and COPD; therefore, it cannot be considered a specific phenotype of any of them. As expected, Th2-related cytokines (IL-13 and IL-5) exhibited highest median values in asthma and lowest median values in COPD with intermediate results in ACO. Inversely, IL-8 was found to be significantly increased in patients with a smoking history (COPD and ACO) in comparison with asthma. Periostin levels were not useful to distinguish between categories, but they were increased in those with a more predictable "Th2-high signature" (asthma and ACO) with respect to COPD. Interestingly, IL-13 was the most connected node of the inflammome in the three conditions. Taken together, these findings are congruent with the heterogeneous inflammatory background of COAD patients, probably a continuum between non-Th2 and Th2 inflammation with substantial overlap in a high proportion of cases.

Since several biologic therapies are now being tested in asthma and COPD, the identification of biological markers reflecting the underlying disease process seems to be of particular relevance to implementing more personalized approaches to therapeutic decisions in airway disease. However, to date, very few studies have addressed the underlying mechanisms of inflammation in ACO. Kitaguchi et al,[@b10-copd-13-591] in a retrospective study with a small sample size, found that COPD patients with asthmatic symptoms had high peripheral and sputum eosinophil counts and better reversibility response to treatment with ICSs. On the other hand, Gao et al[@b11-copd-13-591] aimed at finding sputum biomarkers capable of differentiating between ACO, COPD, and asthma patients. They found that only sputum neutrophil gelatinase-associated lipocalin levels were significantly increased in patients with ACO in comparison with the asthma and COPD groups. In this study, sputum IL-13 was increased in asthma, COPD, and ACO in comparison with healthy and smoker controls, which could be sustaining the central role in the inflammome we found in our study. However, since the definitions of the different diagnostic categories are somewhat arbitrary and based on nonspecific clinical features, the design of this study was subjected to the same limitations as all the previously published studies on this topic. In theory, it would be expected to find some evidence of Th1 inflammation (characteristic, but not pathognomonic of COPD) and some evidence of Th2 inflammation (characteristic, but not pathognomonic of asthma) in patients with ACO.[@b12-copd-13-591] Unfortunately, there is a lack of reliable Th1 biomarkers; therefore, we have to rely on the assumption that individuals with a smoking history and "fixed bronchial obstruction" who show some evidence of Th2 inflammation can accurately be classified as ACO.[@b13-copd-13-591] Our finding of intermediate IL-5 and IL-13 levels in ACO categories, when compared to asthma and COPD, could give some support to this hypothesis.

Based on DA results, we were unable to find meaningful clusters of association between the different biomarkers, and in consequence, we were not able to demonstrate a link between the three clinical categories of COAD (asthma, COPD, and ACO) with clearly defined different inflammatory patterns. However, a network representation of the interaction between the inflammatory markers yielded two clearly different networks that overlap in ACO. This supports the hypothesis that inflammatory pattern observed in ACO is a blend of COPD and asthma components.

Overall, the correlation between biomarkers was poor. The weak correlation found between blood eosinophils and Th2-high cytokines (IL-5 and IL-13) was of particular interest because it contradicts the results obtained by Agache et al,[@b14-copd-13-591] who observed an almost perfect (r\>0.90) association between these variables in 64 adult asthmatics. Our results were not different when we analyzed separately the correlation of these biomarkers in the asthma group, although it should be taken into account that all of our patients showed "fixed bronchial obstruction," whereas this feature was only present in 6% of Agache et al's sample, which might reflect notable differences in the studied populations.

Two reasons could help to explain the observed lack of association between clinical categories and putative biomarkers. First, it has been reported that asthma and COPD demonstrate a significant overlap in the airway cytokine profile, which suggests the coexistence of different phenotypes of COAD sharing a common cytokine network.[@b15-copd-13-591],[@b16-copd-13-591] The central role of IL-13 and IL-17 in the network would be in keeping with this result. Moreover, we should bear in mind that asthma and COPD are themselves heterogeneous diseases with various inflammatory phenotypes. Solleiro-Villavicencio et al[@b17-copd-13-591] observed that the inflammatory response induced by the exposure to biomass smoke differs greatly from that caused by tobacco smoking, and Khurana et al[@b18-copd-13-591] found that "COPD persistent sputum producers" have increased concentrations of some inflammatory mediators in the airways when compared to nonpersistent sputum producers. On the other hand, Seys et al[@b19-copd-13-591] found five different asthma clusters based on sputum cytokine expression, which underscores the heterogeneity in airway inflammation among different asthma patients. Taken together, these studies point out a patient-to-patient variability of the inflammatory markers in individuals with COAD. Second, there seems to be no clear correlation between biomarkers in systemic and pulmonary compartments. Although serum cytokines have shown sufficient reliability and repeatability over time, several authors observed only few and weak associations between lung and serum biomarkers, both in COPD[@b20-copd-13-591],[@b21-copd-13-591] and asthma patients.[@b22-copd-13-591] Thus, it is possible that measuring serum cytokines does not sufficiently reflect the inflammatory processes within the airways.

As described in detail previously,[@b5-copd-13-591] "our work has several limitations that deserve a comment. First, we used arbitrary cutoff points of blood eosinophil to recruit patients and to define Th2 profile, but we used the available published information that supports this view. However, we were more stringent in the definition of Th2, using a cutoff of 300 cells/µL, which is widely accepted.[@b23-copd-13-591] In addition, a large number of patients were receiving ICSs, and some of them were being treated with oral corticosteroids or omalizumab, which could have an effect masking differences between groups and modifying the expression of Th2 biomarkers such as blood/sputum eosinophils and serum cytokines. Third, the limit of 20 pack-years of smoking exposure in asthmatics could be too artificially high. However, by doing so, we make sure that this phenotype is going to overlap the characteristics of smoking-related inflammation on the top of the baseline asthmatic inflammation."

Conclusion
==========

The heterogeneity of asthma and COPD induces different inflammatory pathways that coexist in ACO, being IL-13 the common node orchestrating the inflammome in these conditions. Nevertheless, neither non-Th2-related nor Th2-related serum cytokines or periostin (alone or combined) permitted to distinguish between COAD categories or to predict a Th2-high inflammatory pattern.
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###### 

Biomarker AUC in the ROC for the diagnosis of the different COAD categories, alone and in combination

  ----------------------------------------------------------------------
  Biomarker           Asthma           COPD             ACO
  ------------------- ---------------- ---------------- ----------------
  IL-13 (pg/mL)       0.564\           0.532\           0.531\
                      (0.490--0.637)   (0.458--0.605)   (0.463--0.599)

  IL-5 (pg/mL)        0.587\           0.600\           0.508\
                      (0.515--0.659)   (0.528--0.672)   (0.440--0.577)

  IL-17 (pg/mL)       0.563\           0.578\           0.511\
                      (0.492--0.635)   (0.503--0.653)   (0.444--0.579)

  IL-6 (pg/mL)        0.587\           0.578\           0.489\
                      (0.514--0.659)   (0.506--0.650)   (0.422--0.557)

  IL-8 (pg/mL)        0.652\           0.567\           0.581\
                      (0.583--0.720)   (0.497--0.637)   (0.513--0.649)

  TNF-α (pg/mL)       0.506\           0.527\           0.530\
                      (0.435--0.577)   (0.450--0.604)   (0.462--0.597)

  IL-13/IL-8          0.608\           0.551\           0.555\
                      (0.564--0.706)   (0.479--0.623)   (0.486--0.624)

  IL-5/IL-8           0.635\           0.605\           0.531\
                      (0.564--0.706)   (0.533--0.677)   (0.464--0.599)

  Periostin (ng/mL)   0.558\           0.549\           0.573\
                      (0.483--0.632)   (0.480--0.618)   (0.505--0.641)
  ----------------------------------------------------------------------

**Note:** Data shown as area under the curve (confidence interval 95%).

**Abbreviations:** ACO, asthma--COPD overlap; AUC, area under the ROC; COAD, chronic obstructive airway disease; COPD, chronic obstructive pulmonary disease; ROC, receiver operating curve; TNF-α, tumor necrosis factor-α.
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![Flowchart diagram of recruitment process.\
**Abbreviations:** ACO, asthma--COPD overlap; COPD, chronic obstructive pulmo nary disease. FEV~1~, forced expiratory volume in the first second; FVC, forced vital capacity.](copd-13-591Fig1){#f1-copd-13-591}

![Cytokine concentrations in asthma, ACO, and COPD.\
**Notes:** \**p*\<0.05 vs asthma; \*\**p*\<0.001 vs asthma.\
**Abbreviations:** ACO, asthma--COPD overlap; COPD, chronic obstructive pulmonary disease; TNF-α, tumor necrosis factor-α.](copd-13-591Fig2){#f2-copd-13-591}

![Scatterplot of the combination of values from discriminant scores 1 and 2 as compared to each patient's COAD category.\
**Abbreviations:** COAD, chronic obstructive airway disease; COPD, chronic obstructive pulmonary disease; COPD-e, COPD with eosinophilia; NSA, nonsmoking asthmatics; SA, smoking asthmatics.](copd-13-591Fig3){#f3-copd-13-591}

![Network layout of inflammome in asthma, COPD, and ACO.\
**Abbreviations:** ACO, asthma--COPD overlap; COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide; TNF-α, tumor necrosis factor-α.](copd-13-591Fig4){#f4-copd-13-591}

###### 

Characteristics of patients according to the baseline diagnosis

                                   Asthma           COPD            ACO               *p*-value
  -------------------------------- ---------------- --------------- ----------------- -----------
  Number of subjects               94               89              109               
  Age (years)                      61.8 (12.3)      67.9 (8.6)      63.31 (10.6)      \<0.001
  Gender (% female)                55.3             24.7            34.9              \<0.001
  BMI (kg/m^2^)                    28.6 (4.7)       28.4 (4.9)      28.6 (6)          0.96
  Pack-years                       3.4 (5.8)        48.7 (22.5)     45.1 (24)         \<0.001
  Positive SPT (%)                 46.8             7.9             32.1              \<0.001
  Rhinitis (%)                     53.2             9.3             31.1              \<0.001
  Pre-BD FEV~1~ (%)                61.2 (17.7)      51.4 (18.2)     53.8 (16.5)       \<0.001
  Post-BD FEV~1~ (%)               69.5 (18.9)      55.1 (18.5)     58.9 (17)         \<0.001
  PBT (%)                          44.6             19.2            37.7              0.001
  DLCO (%)                         83.4 (18.7)      63.6 (25.9)     66.6 (19.1)       \<0.001
  Exacerbations in previous year   0.97 (1.37)      1.08 (1.32)     0.97 (1.36)       0.92
  Blood eosinophils (cells/µL)     300 (0, 4,350)   100 (0, 200)    300 (0, 1,000)    \<0.001
  Sputum eosinophils (n=35, %)     4.8 (5.8)        1.8 (2.1)       6.3 (5.8)         0.21
  IgE (IU/mL)                      123 (4, 2,909)   51 (4, 2,301)   89.8 (4, 2,500)   0.094
  FeNO (ppb)                       36.0 (24.1)      17.3 (9.6)      22.5 (21)         \<0.001
  CAT                              14.8 (8.8)       13.0 (6.7)      13.3 (7.7)        0.83
  ACT                              20.2 (4.4)       20.4 (4.3)      19.4 (4.8)        0.54
  ICS (%)                          100              66.3            75.2              \<0.01
  LABA (%)                         99               93.3            93.6              0.19
  LAMA (%)                         54.3             87.6            73.4              \<0.01

**Notes:** Data are expressed as mean (SD), median (percentile 25, percentile 75), or n and %. Overall *p*-values are reported. Exacerbations: number of severe exacerbations during the past 12 months.

**Abbreviations:** ACO, asthma--COPD overlap; ACT, asthma control test; BMI, body mass index; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; DLCO, carbon monoxide diffusing capacity; FeNO, fractioned exhaled nitric oxide levels; FEV~1~, forced expiratory volume in the first second; ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic antagonists; PBT, positive bronchodilator test; post-BD, post-bronchodilator; pre-BD, pre-bronchodilator; SPT, skin prick test.

###### 

Biomarker values according to the baseline diagnosis

                      Asthma (n=94)        COPD (n=89)                                                        ACO (n=109)                                                        *p*-value
  ------------------- -------------------- ------------------------------------------------------------------ ------------------------------------------------------------------ -----------
  IL-6 (pg/mL)        1.77 (0.71--3.66)    1.13 (0.43--2.30)[\*](#tfn4-copd-13-591){ref-type="table-fn"}      1.42 (0.57--2.44)                                                  0.031
  IL-8 (pg/mL)        7.03 (4.69--10.44)   9.45 (6.61--13.12)[\*\*](#tfn5-copd-13-591){ref-type="table-fn"}   9.58 (6.39--13.51)[\*\*](#tfn5-copd-13-591){ref-type="table-fn"}   \<0.001
  TNF-α (pg/mL)       3.93 (3.11--5.50)    4.21 (2.57--5.68)                                                  4.17 (3.22--5.43)                                                  0.660
  IL-13 (pg/mL)       2.98 (0.23--7.63)    1.25 (0.23--5.31)                                                  1.98 (0.23--9.92)                                                  0.213
  IL-5 (pg/mL)        2.09 (0.61--3.57)    1.11 (0.12--2.42)[\*](#tfn4-copd-13-591){ref-type="table-fn"}      1.73 (0.41--2.77)                                                  0.012
  Periostin (ng/mL)   37.4 (26.6--49.2)    33.5 (27.7--49.9)                                                  35 (27.9--44)                                                      0.232
  IL-17 (pg/mL)       6.94 (3.11--15.90)   5.33 (1.41--11.37)                                                 6.75 (2.64--12.47)                                                 0.075
  IL-13/IL-8          0.43 (0.05--0.63)    0.15 (0.04--0.56)                                                  0.14 (0.03--0.53)                                                  0.013
  IL-5/IL-8           0.25 (0.08--0.63)    0.12 (0.02--0.25)                                                  0.14 (0.05--0.29)                                                  \<0.001
  FeNO (ppb)          33 (19.8--41.3)      17.3 (12--18.8)[\*\*](#tfn5-copd-13-591){ref-type="table-fn"}      19.6 (10--24.6)[\*\*](#tfn5-copd-13-591){ref-type="table-fn"}      \<0.001

**Notes:** Overall *p*-values from Kruskal--Wallis ANOVA; pairwise *p*-values from Mann--Whitney *U*-test, Bonferroni-corrected:

*p*\<0.05 vs asthma;

*p*\<0.001 vs asthma.

**Abbreviations:** ACO, asthma--COPD overlap; ANOVA, analysis of variance; COPD, chronic obstructive pulmonary disease; FeNO, fractional exhaled nitric oxide; TNF-α, tumor necrosis factor-α.

###### 

Blood biomarkers in Th2-high and Th2-low patients

  -----------------------------------------------------------------------------
                      Th2-high pattern\      Th2-low pattern\       *p*-value
                      (n=94)                 (n=197)                
  ------------------- ---------------------- ---------------------- -----------
  IL-6 (pg/mL)        1.75 (0.58--2.67)      1.31 (0.50--2.63)      0.174

  IL-8 (pg/mL)        8.34 (5.37--12.77)     8.40 (5.88--12.77)     0.856

  TNF-α (pg/mL)       4.32 (3.20--6.16)      3.95 (2.91--5.32)      0.055

  IL-13 (pg/mL)       2.92 (0.26--5.59)      1.65 (0.23--5.58)      0.150

  IL-5 (pg/mL)        1.96 (0.87--3.34)      1.51 (0.29--2.88)      0.025

  Periostin (ng/mL)   39.73 (28.05--54.40)   34.20 (26.94--41.43)   0.005

  IL-13/IL-8          0.26 (0.06--0.66)      0.15 (0.03--0.78)      0.182

  IL-5/IL-8           0.23 (0.08--0.40)      0.13 (0.03--0.33)      0.019

  IL-17 (pg/mL)       7.37 (3.46--13.76)     5.73 (2.10--12.12)     0.125
  -----------------------------------------------------------------------------

**Notes:** Data are expressed as medians and interquartile ranges; *p*-values from the Mann--Whitney *U*-test.

**Abbreviation:** TNF-α, tumor necrosis factor-α.

###### 

Biomarker ROC and best cutoff point to predict Th2-high or Th2-low patterns

  Biomarker             ROC            Value
  --------------------- -------------- ----------------------
  IL-6                  AUC (95% CI)   0.550 (0.479--0.620)
  Best cutoff (pg/mL)   NA             
  IL-8                  AUC (95% CI)   0.507 (0.434--0.579)
  Best cutoff (pg/mL)   NA             
  TNF-α                 AUC (95% CI)   0.570 (0.499--0.641)
  Best cutoff (pg/mL)   4.04           
  IL-13                 AUC (95% CI)   0.552 (0.482--0.623)
  Best cutoff (pg/mL)   NA             
  IL-5                  AUC (95% CI)   0.582 (0.512--0.652)
  Best cutoff (pg/mL)   1.79           
  Periostin             AUC (95% CI)   0.602 (0.528--0.677)
  Best cutoff (IU/mL)   35.2           
  IL-5 + IL-13          AUC (95% CI)   0.579 (0.508--0.650)
  IL-5 + IL-13 + IL-8   AUC (95% CI)   0.593 (0.523--0.662)
  IL-13/IL-8            AUC (95% CI)   0.549 (0.479--0.619)
  IL-5/IL-8             AUC (95% CI)   0.586 (0.517--0.654)
  Best cutoff           0.15           
  IL-17                 AUC (95% CI)   0.556 (0.486--0.626)
  Best cutoff (pg/mL)   NA             

**Abbreviations:** AUC, area under the ROC; CI, confidence interval; NA, not applicable; ROC, receiver operating curve; TNF-α, tumor necrosis factor-α.

[^1]: These authors contributed equally to this work
